● Recruiting

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

Condition: Metastatic Solid Tumor · Brain Metastases · Sponsor: M.D. Anderson Cancer Center

PhasePhase 2

Planned participants30

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

To learn if the study drugs, tucatinib and adotrastuzumab emtansine (T-DM1), can help to control solid tumors that have spread to the brain.

This description comes directly from the study's public registry record.

Talk to the study team

Ecaterina Dumbrava, MD · 713-563-1930 · eeileana@mdanderson.org

Always discuss trial participation with your own doctor first.

Locations (1)

M D Anderson Cancer Center

Houston, Texas, United States

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05673928